- Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024€24.4 (+5.17%)Earnings
- EyePoint Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- EyePoint Pharmaceuticals Inc Conference call to discuss topline results TranscriptDec 04, 2023
- EyePoint Pharmaceuticals Inc to Host Virtual Key Opinion Leader TranscriptNov 09, 2023
- Q3 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 01, 2023€5.6 (+0.90%)Earnings
- EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - Panel Discussion TranscriptAug 16, 2023
- EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - On-demand TranscriptAug 16, 2023
- Q2 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 02, 2023€10.9 (-2.68%)Earnings
- EyePoint Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 03, 2023€5.8 (-3.33%)Earnings
- EyePoint Pharmaceuticals Inc at Guggenheim Healthy Altitudes Summit TranscriptMar 15, 2023
- Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 02, 2023€2.9 (-7.05%)Earnings
- Q3 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2022€5.5 (+0.92%)Earnings
- Q2 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2022€9.05 (+4.02%)Earnings
- EyePoint Pharmaceuticals Inc Investor Day TranscriptJul 18, 2022
- Q1 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2022€11.2 (-0.88%)Earnings
- EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 28, 2022
- Q4 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 03, 2022€8.75 (-3.31%)Earnings
- EyePoint Pharmaceuticals Inc Phase 1 DAVIO Trial Of EYP-1901 Results Conference Call TranscriptNov 13, 2021
- Q3 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2021€10.6 (+1.92%)Earnings
- EyePoint Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2021€7.1 (+2.16%)Earnings
- Q1 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2021€8.7 (-1.14%)Earnings
- Q4 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 04, 2021€9.6 (-4.00%)Earnings
- EyePoint Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 03, 2021
- EyePoint Pharmaceuticals Inc to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD TranscriptDec 04, 2020
- Q3 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020€3.8 (+23.38%)Earnings
- Q2 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2020€6.06 (-0.98%)Earnings
- Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2020€8.1 (-6.36%)Earnings
- Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020€13.1 (-25.14%)Earnings
- Q3 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019€16 (-22.33%)Earnings
- Q2 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019€11.03 (+1.75%)Earnings
- Q1 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019€14.53 (-2.22%)Earnings
- EyePoint Pharmaceuticals Inc Six-Month Transition Period Ended December 31, 2018 Earnings Call TranscriptMar 14, 2019€22.5 (-1.75%)Earnings
EyePoint Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning, everyone. Thank you for joining the EyePoint Pharmaceuticals presentation on day three of the JPMorgan Healthcare Conference. I'm [Wanhee Yeo], from the JPMorgan Healthcare Investment Banking team. And it's my pleasure to be introducing you to Dr. Jay Duker, President and Chief Executive Officer of EyePoint Pharmaceuticals.
Thank you very much, and thanks all for coming and listening this morning. We are a publicly traded company. And as such, I will be making some forward-looking statements. And if you need any more information on that, please feel free to visit our website.
EyePoint in its heart is a drug delivery company to the back of the eye. Our lead product is called EYP-1901. It's a combination of vorolanib, which is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors and is placed into our patented Durasert E delivery system. E is for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)